Department of Biochemistry, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates.
PLoS One. 2013;8(2):e55993. doi: 10.1371/journal.pone.0055993. Epub 2013 Feb 7.
Manuka honey has been recognized for its anti-bacterial and wound-healing activity but its potential antitumor effect is poorly studied despite the fact that it contains many antioxidant compounds. In this study, we investigated the antiproliferative activity of manuka honey on three different cancer cell lines, murine melanoma (B16.F1) and colorectal carcinoma (CT26) as well as human breast cancer (MCF-7) cells in vitro. The data demonstrate that manuka honey has potent anti-proliferative effect on all three cancer cell lines in a time- and dose-dependent manner, being effective at concentrations as low as 0.6% (w/v). This effect is mediated via the activation of a caspase 9-dependent apoptotic pathway, leading to the induction of caspase 3, reduced Bcl-2 expression, DNA fragmentation and cell death. Combination treatment of cancer cells with manuka and paclitaxel in vitro, however, revealed no evidence of a synergistic action on cancer cell proliferation. Furthermore, we utilized an in vivo syngeneic mouse melanoma model to assess the potential effect of intravenously-administered manuka honey, alone or in combination with paclitaxel, on the growth of established tumors. Our findings indicate that systemic administration of manuka honey was not associated with any alterations in haematological or clinical chemistry values in serum of treated mice, demonstrating its safety profile. Treatment with manuka honey alone resulted in about 33% inhibition of tumor growth, which correlated with histologically observable increase in tumor apoptosis. Although better control of tumor growth was observed in animals treated with paclitaxel alone or in combination with manuka honey (61% inhibition), a dramatic improvement in host survival was seen in the co-treatment group. This highlights a potentially novel role for manuka honey in alleviating chemotherapy-induced toxicity.
麦卢卡蜂蜜因其抗菌和伤口愈合活性而受到认可,但尽管它含有许多抗氧化化合物,但其潜在的抗肿瘤作用仍研究甚少。在这项研究中,我们研究了麦卢卡蜂蜜对三种不同的癌细胞系,即鼠黑色素瘤(B16.F1)和结直肠癌(CT26)以及人乳腺癌(MCF-7)细胞的体外增殖活性。数据表明,麦卢卡蜂蜜对所有三种癌细胞系均具有强大的抗增殖作用,呈时间和剂量依赖性,在低至 0.6%(w/v)的浓度下就有效。这种作用是通过激活 caspase 9 依赖性凋亡途径介导的,导致 caspase 3 的诱导、Bcl-2 表达的减少、DNA 片段化和细胞死亡。然而,体外联合使用麦卢卡蜂蜜和紫杉醇治疗癌细胞,并未显示对癌细胞增殖有协同作用的证据。此外,我们利用体内同源小鼠黑色素瘤模型来评估静脉内给予麦卢卡蜂蜜,单独或与紫杉醇联合使用,对已建立的肿瘤生长的潜在影响。我们的研究结果表明,全身性给予麦卢卡蜂蜜不会导致治疗小鼠血清中的血液学或临床化学值发生任何改变,证明了其安全性。单独使用麦卢卡蜂蜜治疗导致肿瘤生长抑制约 33%,这与组织学上观察到的肿瘤凋亡增加相关。虽然单独用紫杉醇或与麦卢卡蜂蜜联合治疗的动物中观察到肿瘤生长得到更好的控制(抑制 61%),但在联合治疗组中观察到宿主存活有显著改善。这突出了麦卢卡蜂蜜在减轻化疗引起的毒性方面的潜在新作用。